Closed-loop FiO2 Controller During High Flow Oxygen Treatment In Pediatric Patients (COFICOHFOT)

Sponsor
Dr. Behcet Uz Children's Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05032365
Collaborator
(none)
19
2
2
5
9.5
1.9

Study Details

Study Description

Brief Summary

Recently, high flow oxygen therapy (HFOT) is becoming more popular in the treatment of any kind of respiratory failure. Pediatric mechanical ventilation consensus conference (PEMVECC) guidelines suggest measuring oxygen saturation by pulse oximetry (SpO2) in all ventilated children and furthermore to measure partial arterial oxygen pressure (PaO2) in moderate-to-severe disease in order to prevent excessive use of oxygen while preventing hypoxemia and hyperoxemia. This study aims to compare the safety and efficacy of a closed-loop FiO2 controller (CLOC) with conventional control of FiO2 during HFOT of pediatric patients in a pediatric intensive care unit (PICU). The hypothesis of this study is: Close-loop FiO2 controller increases the time spent within clinically targeted SpO2 ranges and decreases the time spent outside clinical target SpO2 ranges as compared to manual oxygen control in PICU patients treated with HFOT.

Condition or Disease Intervention/Treatment Phase
  • Device: Close-loop FiO2 controller
  • Device: Conventional
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
19 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Randomized Crossover Trial To Compare Closed-loop FiO2 Controller With Conventional Control of FiO2 During High Flow Oxygen Treatment In Pediatric Intensive Care Unit Patients
Actual Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Feb 1, 2022
Anticipated Study Completion Date :
Feb 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Close-loop FiO2 Controller

Two hours period where the fraction of inspired oxygen (FiO2) delivered will be automatically titrated based on SpO2 values obtained from the patient.

Device: Close-loop FiO2 controller
Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.

Active Comparator: Conventional

Two hours period where the FiO2 delivered will be conventionally adjusted by the healthcare personnel based on SpO2 values obtained from the patient.

Device: Conventional
Conventional FiO2 adjustment by the clinician according to SpO2 values

Outcome Measures

Primary Outcome Measures

  1. Percentage of time spent in optimal SpO2 range [2 hours]

    The optimal SpO2 range will be defined according to the SpO2 targets determined by the clinician.

Secondary Outcome Measures

  1. Percentage of time spent in sub-optimal SpO2 range [2 hours]

    SpO2 values outside the optimal range but still within an acceptable limit (2-3 percent above and below the optimal range)

  2. Mean FiO2 [2 hours]

    Mean fraction of inspired oxygen

  3. Mean SpO2/FiO2 [2 hours]

    Mean SpO2/FiO2 oxygen

  4. Number of manual adjustments [2 hours]

    Frequency of manual adjustments of FiO2

  5. Number of alarms [2 hours]

    Frequency of alarms

  6. Percentage of time with SpO2 signal available [2 hours]

    Time with SpO2 signal available

  7. Percentage of time with SpO2 below 88 and 85 percent [2 hours]

    Duration of time with SpO2 <85 percent and <88 percent, respectively

  8. Number of events with SpO2 below 88 and 85 percent [2 hours]

    Frequency of SpO2 decreases <85 percent and <88 percent, respectively

  9. Percentage of time with FiO2 below 40 percent, 60 percent and 100 percent [2 hours]

    Percentage of time that FiO2 is <40 percent, 60 percent and 100 percent, respectively

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Pediatric patients older than 1 month and younger than18 years of age; hospitalized at the PICU with the intention of treatment with HFOT at least for the upcoming 5 hours

  • Requiring FiO2 ≥ 25% to keep SpO2 in the target ranges defined by the clinician

  • Written informed consent signed and dated by the patient or one relative in case that the patient is unable to consent, after full explanation of the study by the investigator and prior to study participation

Exclusion Criteria:
  • Patient with indication for immediate noninvasive ventilation (NIMV), or invasive mechanical ventilation (IMV)

  • Hemodynamic instability defined as a need of continuous infusion of epinephrine or norepinephrine > 1 mg/h

  • Low quality on the SpO2 measurement using finger and ear sensor (quality index below 60% on the SpO2 sensor, which is displayed by a red or orange colour bar)

  • Severe acidosis (pH ≤ 7.25)

  • Pregnant woman

  • Patients deemed at high risk for the need of mechanical ventilation within the next 5 hours

  • Patients deemed at high risk for the need of transportation from PICU to another ward, diagnostic unit or any other hospital

  • Diseases or conditions which may affect transcutaneous SpO2 measurement such as chronic or acute dyshemoglobinemia: methemoglobinemia, carbon monoxide (CO) poisoning, sickle cell disease

  • Formalized ethical decision to withhold or withdraw life support

  • Patient included in another interventional research study under consent

  • Patient already enrolled in the present study in a previous episode of acute respiratory failure

Contacts and Locations

Locations

Site City State Country Postal Code
1 Erzurum Regional Research and Training Hospital Erzurum Turkey 25180
2 The Health Sciences University Izmir Behçet Uz Child Health and Diseases Research and Training Hospital Izmir Turkey 35200

Sponsors and Collaborators

  • Dr. Behcet Uz Children's Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Hasan ağın, Professor doctor, Head of pediatric intensive care unit (PICU), Dr. Behcet Uz Children's Hospital
ClinicalTrials.gov Identifier:
NCT05032365
Other Study ID Numbers:
  • 604/2021/13-01/
First Posted:
Sep 2, 2021
Last Update Posted:
Sep 29, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hasan ağın, Professor doctor, Head of pediatric intensive care unit (PICU), Dr. Behcet Uz Children's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 29, 2021